Drug intelligence / Profile preview

luvagrobart

Development stage: Phase 1
Lead developer: Akeso
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Subcutaneous Injection

Overview

Luvagrobart (AK115) is a humanized IgG1 monoclonal antibody that targets nerve growth factor (NGF). It is developed as an anti-NGF therapy for pain management, including cancer pain. By binding to and inhibiting NGF, it aims to reduce pain signaling. The drug has demonstrated favorable safety and tolerability in phase I clinical trials with healthy subjects, showing predictable pharmacokinetic and pharmacodynamic profiles. Luvagrobart is being developed by Akeso Biopharma primarily for analgesia indications[2][3][4][5][6].

Other names: NGF monoclonal antibody (Akeso)luvagrobart

Targets

NGF (Nerve growth factor)

Beyond the preview

Go deeper on luvagrobart.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on luvagrobart.

Explore the full profile